Category Specific RSS

xanamem

Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank

Shares in drug development company Actinogen Medical (ASX: ACW) have plummeted following the results release of their Phase 2a clinical…

1 year ago

New trial results from Actinogen hold promise for Alzheimer’s treatment

Most people experience some level of cognitive decline as they get older. It’s a cruel, albeit normal part of the…

3 years ago

Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome

Estimated to affect 1 in every 4,000 boys, there is currently no treatment approved in the world for cognitive disorder…

4 years ago

Better than a sudoku: could this drug be the key to preventing Alzheimer’s?

Our minds can be our greatest asset and our biggest enemy. The same humans that built aeroplanes, rockets and the…

4 years ago